DPP4 and heart failure: Heart failure risks associated with several DPP4 inhibitors have been assessed in randomized clinical trials, meta-analyses, and observational studies, producing conflicting results ranging from reduced risk [3, 17, 18], to no risk [7, 9, 11, 12, 30–32], to high risk [8, 16, 30, 33–35] of heart failure.